Clinical Trial

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study was designed to compare the efficacy and safety of YL201 with Topotecan Hydrochloride in subjects with relapsed small cell lung cancer (SCLC).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-09-23; most recent amendment 2026-05-21.
Status change: Recruiting → Active, Not Recruiting 2026-05-21
Status change: Not Yet Recruiting → Recruiting 2025-02-07
Trial Details
NCT Number NCT06612151
Lead Sponsor MediLink Therapeutics (Suzhou) Co., Ltd.
Conditions Small Cell Lung Cancer
Enrollment 438 participants
Start Date 2024-12-17
Primary Completion 2027-12-01 (estimated)
Study Completion 2030-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-26